Metagenomi, Inc. (NASDAQ:MGX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven ratings firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $15.50.
Several equities analysts recently weighed in on MGX shares. Chardan Capital reiterated a "buy" rating and set a $15.00 target price on shares of Metagenomi in a research report on Wednesday, November 20th. HC Wainwright restated a "buy" rating and issued a $7.00 price objective on shares of Metagenomi in a research report on Thursday, November 21st. Finally, BMO Capital Markets lowered their price objective on Metagenomi from $22.00 to $17.00 and set an "outperform" rating on the stock in a research report on Thursday, August 15th.
View Our Latest Analysis on MGX
Institutional Investors Weigh In On Metagenomi
Several large investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in shares of Metagenomi in the third quarter worth about $33,000. Geode Capital Management LLC increased its holdings in shares of Metagenomi by 105.8% in the third quarter. Geode Capital Management LLC now owns 338,031 shares of the company's stock worth $734,000 after purchasing an additional 173,796 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in shares of Metagenomi by 209.4% in the third quarter. Jacobs Levy Equity Management Inc. now owns 136,624 shares of the company's stock worth $296,000 after purchasing an additional 92,468 shares during the last quarter. Verition Fund Management LLC bought a new stake in Metagenomi during the third quarter worth approximately $82,000. Finally, BNP Paribas Financial Markets increased its stake in Metagenomi by 130.9% during the third quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company's stock worth $28,000 after acquiring an additional 7,256 shares during the last quarter.
Metagenomi Price Performance
NASDAQ MGX traded down $0.01 on Thursday, hitting $1.85. 472,721 shares of the company traded hands, compared to its average volume of 197,014. The business's 50 day moving average price is $1.99 and its 200-day moving average price is $3.41. Metagenomi has a 52-week low of $1.61 and a 52-week high of $12.74.
Metagenomi Company Profile
(
Get Free ReportMetagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.
Featured Articles
Before you consider Metagenomi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metagenomi wasn't on the list.
While Metagenomi currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
